zidovudine and lamivudine (Combivir®)

Phase 3

Gilead Sciences, Inc. (GILD)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in HIV Infections

AGY.LAnti-HIV Immune Serum Globulin (Human)

Drug Information

Target Indication

HIV Infections

Clinical Trial

NCT00323544

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/18/1998

Combivir

Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

ZimberelimabPhase 3

Head and Neck Squamous Cell Carcinoma

LenacapavirPhase 3

HIV Prevention

MagrolimabPhase 3

Myelodysplastic Syndrome

MTXPhase 3

Rheumatoid Arthritis

StribildPhase 3

Acquired Immunodeficiency Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts